莎普爱思：关于立他司特滴眼液Ⅲ期临床试验完成首例受试者入组的公告

Core Viewpoint - The company, Shapais, announced the completion of the first subject enrollment in the Phase III clinical trial for its drug, Litasite Eye Drops [2] Group 1 - The company organized the Phase III clinical trial for Litasite Eye Drops [2] - The announcement was made on the evening of October 24 [2] - The trial has successfully enrolled its first participant [2]